The FDA recently granted fast track designation to PHST001, an investigational anti-CD24 monoclonal antibody, for the ...

The FDA grants fast track designation to PHST001, an antibody targeting CD24, for advanced platinum-resistant and ...

In the final part of an interview with Brian Slomovitz, MD, he highlights that the phase 3 ROSELLA trial demonstrates a safe, effective treatment for platinum-resistant ovarian cancer that does not ...

A new study explains the genetic underpinnings of a rare and aggressive form of ovarian cancer – and offers a potential ...

Adding IMNN-001 to perioperative chemotherapy showed numerical improvements in PFS and OS for newly diagnosed epithelial ...